Atorvastatin for reduction of 28-day mortality in severe and critical COVID-19 patients: a randomized controlled...

Area of Science:

• Cardiology
• Infectious Diseases
• Critical Care Medicine

Background:

• COVID-19 involves abnormal host response, endothelial dysfunction, and multi-organ failure.
• Atorvastatin, a statin, has been investigated for its potential to mitigate COVID-19 severity.
• Previous hypotheses suggested atorvastatin might reduce COVID-19 severity and mortality.

Purpose of the Study:

• To evaluate the efficacy of atorvastatin in reducing mortality among severe COVID-19 patients.
• To assess the impact of atorvastatin on clinical improvement and hospital stay duration.
• To investigate the effect of atorvastatin on secondary outcomes like acute kidney injury and need for mechanical ventilation.

Main Methods:

• A randomized, double-blind, placebo-controlled trial involving 220 COVID-19 patients.
• Patients received either 40 mg of atorvastatin daily or a placebo for 28 days.
• Primary outcome was 28-day all-cause mortality; secondary outcomes included 6-month mortality, clinical improvement, and length of stay.

Main Results:

• No statistically significant difference in 28-day all-cause mortality between atorvastatin (50%) and placebo (52.4%) groups (P=0.727).
• Six-month mortality also showed no significant difference (52% vs. 60.8%, P=0.208).
• Atorvastatin did not shorten time to clinical improvement or reduce hospital stay duration.

Conclusions:

• Atorvastatin did not demonstrate a significant benefit in reducing mortality for severe or critical COVID-19 patients.
• The drug did not improve clinical recovery times or reduce hospital length of stay.
• Further research may be needed to explore potential benefits in specific patient subgroups or at different stages of the disease.